GlobeNewswire

Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs

Dela

Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj.

För mer information, vänligen kontakta
Henrik Nittmar, VD
Telefon: 018-71 30 90
E-post: henrik.nittmar@corline.se

Certified Adviser
Svensk Kapitalmarknadsgranskning
Telefon: 011-32 30 732
E-post: ca@skmg.se

Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare ytbelägger bolaget medicintekniska produkter och har bland annat behandlat över 100 000 hjärtstentar som implanterats i patienter. De nya läkemedelskandidaterna är baserade på samma grundteknologi som de medicintekniska produkterna.

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Dividend payment ex-date of AS “Latvijas Gāze”6.7.2020 07:45:00 CESTPress release

AS “Latvijas Gāze” (GZE1R, ISIN code LV0000100899) will close the list of shareholders for dividend payment on July 9, 2020 at the end of the working day of the Nasdaq CSD Latvian Settlement System. Proceeding from the above, the ex-date is July 8, 2020. From that date the new owner of the shares is not entitled to the dividends. AS “Latvijas Gāze” will pay dividend 0.44 EUR per share on July 10, 2020. The JSC "Latvijas Gāze" confirms that: - the profit paid in dividends was earned after January 1, 2018; - no conditions permitting the JSC "Latvijas Gāze" to reduce the corporate income tax base under Section 13 of the Corporate Income Tax Law have been applied. Additional information: Madara Ventere Head of Finance and accounting division Phone: + (371) 67 369 281 E-mail: investor.relations@lg.lv www.lg.lv

Idorsia announces positive results in the second Phase 3 study of daridorexant6.7.2020 07:00:00 CESTPress release

Results confirm and reinforce the efficacy and safety profile from the first pivotal studyCompany targets filing the New Drug Application (NDA) around the end of 2020Idorsia to host an investor webcast to discuss the second Phase 3 results today at 14:00hrs CEST Allschwil, Switzerland – July 6, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia. The study confirms the findings of the first pivotal study, demonstrating efficacy of treatment with daridorexant on objective and subjective sleep parameters and showed positive effects on daytime functioning, with patients reporting no morning sleepiness and no evidence of rebound or withdrawal symptoms upon treatment discontinuation. On April 20, 2020, the company reported (media release) the results of the first pivotal study with dar

Airtel deploys India’s largest open cloud-based VoLTE network with Nokia software products6.7.2020 07:00:00 CESTPress release

Press Release FINAL Airtel deploys India’s largest open cloud-based VoLTE network with Nokia software products ·As part of its cloudification strategy, Airtel will deploy Nokia’s CloudBand Infrastructure Software 6 July 2020 Espoo, Finland – Nokia today announced that its CloudBand-based software products are powering Bharti Airtel’s (“Airtel”) Voice over LTE (VoLTE) network in India. The network supports over 110 million customers, making it the largest cloud-based VoLTE network in India and the largest Nokia-run VoLTE in the world. The cloud-based VoLTE deployment allows Airtel to provide its mobile customers faster and more reliable, cost-efficient call connectivity. The solution, which has been deployed to cover all 22 telecom service areas in India, uses Commercial Off-the-Shelf IT hardware with cloud-based Virtual Network Functions (VNFs), which consumes much less power and space compared to the traditional 2G/3G Circuit Switched legacy core. Nokia’s VoLTE solution enables Airtel

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids6.7.2020 07:00:00 CESTPress release

PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52 Results confirm linzagolix as a potential best-in-class GnRH antagonist, with a pooled responder rate of 84.7% for the 200 mg with Add Back Therapy* (ABT) dose from PRIMROSE 1 and 2 Linzagolix is the only GnRH antagonist as a potential unique treatment option for up to 50% of US women with uterine fibroids for whom ABT therapy may be contraindicated Success of PRIMROSE 1 and 2 studies enables progression towards regulatory submissions, anticipated 4Q 2020 in the EU and 1H 2021 in the US GENEVA, Switzerland and BOSTON, MA (July 6, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced top-line results from the PRIMROSE 1 and 2 studies of Ysel

DIAC S.A.: UPDATE OF NEU MTN PROGRAMME3.7.2020 19:32:13 CESTPress release

July, 3rd 2020 DIAC S.A.: UPDATE OF NEU MTN PROGRAMME DIAC S.A. updated the Information Memorandum of its Negotiable Medium Term Notes (NEU MTN Programme). This documentation was approved by the Banque de France is available on its website under the following link: https://eucpmtn.banque-france.fr/public/#/liste-des-emetteurs/5f8b9dec-b611-ea11-80f7-001dd8b71ea9 DIAC S.A. Etablissement de crédit et intermédiaire d’assurances, au capital de 659 334 050 EUR. Siège social : 14, avenue du Pavé Neuf – 93168 Noisy-le-Grand cedex SIREN 702 002 221 RCS Bobigny – N° TVA : FR02 702002221 – Code APE 6492Z – N° ORIAS : 07 004 966 – www.orias.fr Attachment Update DIAC programme NEU MTN 2020

Maha Energy AB (publ) Announce June Production Volumes3.7.2020 17:13:36 CESTPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm July 3, 2020 Maha Energy AB (publ) Announce June Production Volumes Production Volumes The Company's aggregate sales production for the month of June totaled 112,1511 barrels of oil and 57.090 million scf of gas for a combined average production of approximately 4,056 BOE/day2, before royalties and taxes. Other than some minor unplanned shutdowns, production continues to be affected by the impact of the Covid-19 pandemic. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is used. For more information, please contact: Jonas Lindvall (CEO) Tel: +46 8 611 05 11 Email: jonas@mahaenergy.ca or Victoria Berg (Investor Relations) Tel: +46 8 611 05 11 Email: victoria@mahaenergy.ca Maha in Brief Maha Energy AB is a Swedish public limited liability company. FNCA Sweden AB has been engaged as C